. Author manuscript; available in PMC: 2017 Feb 1.

Published in final edited form as: Pediatr Blood Cancer. 2015 Sep 23;63(2):276–286. doi: 10.1002/pbc.25727

Table I.

In vitro activity of selinexor against PPTP cell lines.

Cell Line	Histotype	rIC₅₀ (μM)	Panel rIC₅₀/ Line rIC₅₀	Ymin % (Observed)	P53 Status
RD	Rhabdomyosarcoma	0.128	0.96	1.7	Mutant
Rh41	Rhabdomyosarcoma	0.100	1.22	0.6	Mutant
Rh18	Rhabdomyosarcoma	>10.000	<0.01	69.8	WT
Rh30	Rhabdomyosarcoma	0.065	1.88	1.7	Mutant
BT-12	Rhabdoid	0.085	1.44	3.5	WT
CHLA-266	Rhabdoid	0.048	2.56	2.8	WT
TC-71	Ewing sarcoma	0.247	0.50	0.9	Mutant
CHLA-9	Ewing sarcoma	0.013	9.32	0.0	WT
CHLA-10	Ewing sarcoma	0.040	3.06	2.5	Mutant
CHLA-258	Ewing sarcoma	0.073	1.68	0.5	WT
SJ-GBM2	Glioblastoma	0.101	1.21	0.2	Mutant
NB-1643	Neuroblastoma	0.683	0.18	6.6	WT
NB-EBc1	Neuroblastoma	0.214	0.57	1.6	WT
CHLA-90	Neuroblastoma	0.131	0.94	3.4	Mutant
CHLA-136	Neuroblastoma	0.255	0.48	2.0	WT
NALM-6	ALL	0.077	1.59	0.0	WT
COG-LL-317	ALL	0.042	2.90	0.0	WT
RS4;11	ALL	0.174	0.71	1.1	WT
MOLT-4	ALL	0.317	0.39	0.0	WT
CCRF-CEM (1)	ALL	0.317	0.39	0.2	Mutant
Kasumi-1	AML	0.143	0.86	5.8	Mutant
Karpas-299	ALCL	0.093	1.31	0.2	Mutant
Ramos-RA1	NHL	0.123	1.00	0.0	Mutant
Median		0.123	1.00	1.1
Minimum		0.013	<0.01	0.0
Maximum		>10.000	9.32	69.8